The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 29, 2016

Filed:

Oct. 03, 2013
Applicant:

University of Massachusetts, Boston, MA (US);

Inventors:

Jeanne B. Lawrence, Mapleville, RI (US);

Lisa L. Hall, Sudbury, MA (US);

Assignee:

University of Massachusetts, Boston, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C07H 21/02 (2006.01); C07H 21/04 (2006.01); C12N 15/85 (2006.01); C12N 9/22 (2006.01); C12N 15/113 (2010.01); C12N 15/86 (2006.01); C12N 15/90 (2006.01);
U.S. Cl.
CPC ...
C12N 15/85 (2013.01); A61K 48/005 (2013.01); C12N 9/22 (2013.01); C12N 15/113 (2013.01); C12N 15/86 (2013.01); C12N 15/907 (2013.01); A61K 48/00 (2013.01); C07K 2319/81 (2013.01); C12N 2310/11 (2013.01); C12N 2330/10 (2013.01); C12N 2750/14143 (2013.01);
Abstract

The present invention features compositions and methods for introducing, into cells, nucleic acids whose expression results in chromosomal silencing. The nucleic acids are targeted to specific chromosomal regions where they subsequently reduce the expression of deleterious genes, or cause the death of deleterious cells. Where the nucleic acid sequence is a silencing sequence, it may encode an Xist RNA or other non-coding, silencing RNA. Accordingly, the present invention features, inter alia, nucleic acid constructs that include a transgene (e.g., a silencing sequence encoding an Xist RNA or other non-coding RNA that silences a segment of a chromosome); first and second sequences that direct insertion of the silencing sequence into a targeted chromosome; and, optionally, a selectable marker.


Find Patent Forward Citations

Loading…